MajesTEC-3: Could Teclistamab + Daratumumab Lead to a “Functional Cure” in Myeloma? | IMS 2026

Niels van de Donk, MD, PhD, of Amsterdam UMC discusses a statistical modeling analysis of the MajesTEC-3 trial of teclistamab plus daratumumab at IMS 2026 in Glasgow. He explains what a statistical cure fraction means and why the model suggests many patients on this combination may have a lifespan similar to the general population, a functional cure rather than a cure under the new definition. These are model projections, and longer follow-up is still needed.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction: statistical cure in MajesTEC-3
0:19 MajesTEC-3 trial design: Tec-Dara vs. standard of care
0:40 Better response and survival with Tec-Dara
1:06 The statistical cure fraction: 86%
1:55 Why this is called a functional cure
2:17 The new definition of cure in myeloma
3:29 Cure vs. functional cure